The Filing Desk

Beam Therapeutics vs Regenxbio

Beam Therapeutics BEAM · Regenxbio RGNX · Biotechnology

Regenxbio reported revenue of $170 million in fiscal 2025, 1.2 times Beam Therapeutics' $140 million in fiscal 2025. Beam Therapeutics' revenue grew 120.0% in its latest year, and Regenxbio's grew 104.5%. Beam Therapeutics had an operating margin of -274.6%, against -94.6% at Regenxbio. Free cash flow was −$360 million at Beam Therapeutics and −$126 million at Regenxbio.

Side by side

Beam TherapeuticsRegenxbio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$140M$170M
Revenue growth120.0%104.5%
Revenue growth a year, last 5 years—2.0%
Gross margin——
Operating margin−274.6%−94.6%
Net margin−57.2%−113.8%
Free cash flow−$360M−$126M
Free cash flow margin−257.6%−74.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count20.2%4.2%
Last close$22.83$7.64
P/E at the last close——
Insider trades, last 12 monthssold $18.5 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Beam TherapeuticsRegenxbio
Operating margin
Percent of revenue
Beam TherapeuticsRegenxbio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Beam TherapeuticsRegenxbio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Beam Therapeutics and Regenxbio pages.